Clinical trial
Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
NCT00093119 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00093119 |
|---|---|
| Title | Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma |
| Official title | A Phase II Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma, Metastases |
| Intervention type | Drug |
| Interventions | ABI-007 |
| Enrollment | 75 |
| Start date | Jul 1, 2003 |
| Primary completion | Feb 1, 2005 |
| First posted | Oct 4, 2004 |
| Last update posted | Apr 26, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: